Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor

Purpose: There is an unmet need for noninvasive markers to measure the biological effects of targeted agents, particularly those inhibiting the vascular endothelial growth factor (VEGF) receptor (VEGFR) pathway, and identify patients most likely to benefit from treatment. In this study, we investigated potential blood-based biomarkers for SU11248 (sunitinib malate), a multitargeted tyrosine kinase inhibitor, in patients with metastatic imatinib-refractory gastrointestinal stromal tumors. Experimental Design: Patients (n = 73) enrolled in a phase I/II trial received SU11248 daily for 14 or 28 days followed by 14 days without treatment per cycle. Clinical benefit was defined as progression-free survival of >6 months. We assessed plasma markers, including VEGF and soluble VEGFR-2 (sVEGFR-2), and two cellular populations bearing VEGF receptors: monocytes and, in a subset of patients, mature circulating endothelial cells (CEC). Results: Compared to patients with progressive disease, patients with clinical benefit had significantly greater increases in CECs (0.52 versus −−0.01 CEC/μL/d, P = 0.03) and smaller decreases in monocyte levels (47% versus 60%, P = 0.007) during cycle 1. VEGF increased by 2.2-fold and sVEGFR-2 decreased 25% during the first 2 weeks of treatment. Neither plasma marker correlated with clinical outcome although a modest inverse correlation was observed between sVEGFR-2 changes and plasma drug levels. Monocytes, VEGF, and sVEGFR-2 all rebounded towards baseline off treatment. Conclusions: Monocytes, VEGF, and sVEGFR-2 were consistently modulated by treatment, suggesting that they may serve as pharmacodynamic markers for SU11248. Changes in CECs and monocytes, but not the plasma markers, differed between the patients with clinical benefit and those with progressive disease. These end points merit further investigation in future trials to determine their utility as markers of SU11248 activity and clinical benefit in gastrointestinal stromal tumors and other tumor types.

[1]  A. Goldhirsch,et al.  Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. , 2006, Blood.

[2]  R. Jain,et al.  Differential circulation kinetics during antiangiogenic therapy of four distinct blood cell populations expressing endothelial markers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Voest,et al.  Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F Dignat-George,et al.  Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry , 2006, Cytometry. Part B, Clinical cytometry.

[5]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[6]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Drevs,et al.  Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors , 2005 .

[9]  J. Desai,et al.  Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) , 2005 .

[10]  J. Desai,et al.  Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248 , 2005 .

[11]  J. Folkman,et al.  Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity , 2005, Clinical Cancer Research.

[12]  J. Wood,et al.  Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  B. Peters,et al.  Contribution of bone marrow–derived endothelial cells to human tumor vasculature , 2005, Nature Medicine.

[14]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[15]  R. D'Amato,et al.  Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. , 2005, Cancer cell.

[16]  J. Góra‐Tybor,et al.  Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. , 2005, European cytokine network.

[17]  D. Hicklin,et al.  Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies , 2004, Cancer Research.

[18]  A. D. Van den Abbeele,et al.  Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas , 2004, Clinical Cancer Research.

[19]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[20]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Hicklin,et al.  A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. , 2004, Molecular cancer research : MCR.

[22]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[23]  R. Herbst,et al.  Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors , 2004, Clinical Cancer Research.

[24]  Binodh DeSilva,et al.  Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.

[25]  J. Manola,et al.  Phase II Study of the Antiangiogenic Agent SU 5416 in Patients with Advanced Soft Tissue Sarcomas , 2004 .

[26]  E. Voest,et al.  Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  J. Folkman,et al.  Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. , 2003, Cancer research.

[28]  A. B. Lyons,et al.  Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors , 2003, Leukemia.

[29]  N. Perelman,et al.  Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. , 2003, Blood.

[30]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[31]  H. Kantarjian,et al.  Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. , 2003, Leukemia research.

[32]  T. Robak,et al.  Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. , 2003, European cytokine network.

[33]  R. Herbst,et al.  Surrogate markers in antiangiogenesis clinical trials , 2003, British Journal of Cancer.

[34]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  Rachel Jones.  Ecstasy danger hits the headlines , 2002, Nature Reviews Neuroscience.

[36]  Koichi Hattori,et al.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.

[37]  A. Stopeck,et al.  Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  S. Rafii,et al.  Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment , 2002, Nature Medicine.

[39]  C. Verfaillie,et al.  Origin of endothelial progenitors in human postnatal bone marrow. , 2002, The Journal of clinical investigation.

[40]  A. Krettek,et al.  Expression of PDGF receptors and ligand-induced migration of partially differentiated human monocyte-derived macrophages: Influence of IFN-γ and TGF-β , 2001 .

[41]  G. Pruneri,et al.  Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. , 2001, Cancer research.

[42]  A. Goldhirsch,et al.  Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.

[43]  S. Rafii,et al.  Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells , 2001, The Journal of experimental medicine.

[44]  K. Shitara,et al.  and surface marker for the lineage of monocyte-macrophages in humans Flt-1 , vascular endothelial growth factor receptor 1 , is a novel cell , 2001 .

[45]  A. Harris,et al.  A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  G. Martiny-Baron,et al.  Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. , 2000, Cancer research.

[47]  J. Isner,et al.  VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. , 2000, The Annals of thoracic surgery.

[48]  S. Rafii,et al.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.

[49]  R. Hebbel,et al.  Origins of circulating endothelial cells and endothelial outgrowth from blood. , 2000, The Journal of clinical investigation.

[50]  J. Isner,et al.  VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.

[51]  R. Hebbel,et al.  Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. , 1999, Blood.

[52]  E. Wayner,et al.  Circulating activated endothelial cells in sickle cell anemia. , 1997, The New England journal of medicine.

[53]  A. Mantovani,et al.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.

[54]  U. Testa,et al.  Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. , 1995, Blood.

[55]  Y. Yazaki,et al.  Expression of platelet-derived growth factor beta receptor on human monocyte-derived macrophages and effects of platelet-derived growth factor BB dimer on the cellular function. , 1993, The Journal of biological chemistry.